Acadia Pharmaceuticals (ACAD) Interest Coverage Ratio (2018 - 2019)
Acadia Pharmaceuticals' quarterly Interest Coverage Ratio came in at 4757.58 in Q2 2019, down 1733.87% year-on-year from 291.19 in Q2 2018, and down 1143.22% quarter-over-quarter from 382.68 in Q1 2019.
Acadia Pharmaceuticals has reported Interest Coverage Ratio for 2 years, with the latest figure at 4757.58 in Q2 2019.
- For the quarter ending Q2 2019, Interest Coverage Ratio fell 1733.87% year-over-year to 4757.58; the trailing twelve-month figure through Mar 2020 stood at 20702.17 (down 50866.53% YoY), and the FY2018 full-year result was 27.84, changed N/A from the prior year.
- Interest Coverage Ratio for Q2 2019 stood at 4757.58, down from 382.68 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 35.62 in Q3 2018, with the low at 4757.58 in Q2 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 3.88 |
| 10 | Acadia Pharmaceuticals | 3.69 Bn | 2.84 Bn | 243.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | -4,757.58 |
| Mar 31, 2019 | -382.68 |
| Dec 31, 2018 | -1,015.30 |
| Sep 30, 2018 | -35.62 |
| Jun 30, 2018 | -259.43 |